

Corrigendum: Nano-Theranostics for the Sensing, Imaging and Therapy of Prostate Cancers

David G. Calatayud^{1,2*}, Sotia Neophytou¹, Eleni Nicodemou¹, S. Giuseppe Giuffrida¹, Haobo Ge¹ and Sofia I. Pascu^{1,3*}

¹Department of Chemistry, University of Bath, Bath, United Kingdom, ²Department of Electroceramics, Instituto de Ceramica y Vidrio - CSIC, Madrid, Spain, ³Centre of Therapeutic Innovations, University of Bath, Bath, United Kingdom

Keywords: nanomedicine, theranostics, sensing, imaging, therapy, prostate cancer

A Corrigendum on

Nano-Theranostics for the Sensing, Imaging and Therapy of Prostate Cancers

by Calatayud DG, Neophytou S, Nicodemou E, Giuffrida SG, Ge H and Pascu SI (2022). Front. Chem. 10:830133. doi:10.3389/fchem.2022.830133

In the original article, in the **Funding** statement on page 29, the authors regretably omitted to include the funder "Cancer Research at Bath (CR@B) and membership of the Centre of Therapeutic Innovation at University of Bath for author SIP." The correct **Funding** statement is as follows:

OPEN ACCESS

Edited and reviewed by: Peter Verwilst, KU Leuven, Belgium

*Correspondence:

Sofia I. Pascu s.pascu@bath.ac.uk David G. Calatayud dgcalatayud@icv.csic.es

Specialty section:

This article was submitted to Medicinal and Pharmaceutical Chemistry, a section of the journal Frontiers in Chemistry

> Received: 13 April 2022 Accepted: 14 April 2022 Published: 11 May 2022

Citation:

Calatayud DG, Neophytou S, Nicodemou E, Giuffrida SG, Ge H and Pascu SI (2022) Corrigendum: Nano-Theranostics for the Sensing, Imaging and Therapy of Prostate Cancers. Front. Chem. 10:919505. doi: 10.3389/fchem.2022.919505 "SIP acknowledges funding from ERC Consolidator Grant O2Sense 617107 (2014–2020) and ERC Proof of Concept Grant Tools-To-Sense 963937 (2020–2022), EPSRC (EP/K017160/1 "New manufacturable approaches to the deposition and patterning of graphene materials"), Innovate United Kingdom (previously Technology Strategy Board-CR&D, TS/K001035/1), STFC, University of Bath (UoB) Impact fund, EPSRC Centre for Doctoral Training Centre for Sustainable Chemical Technologies (EP/G03768X/1), Cancer Research at Bath (CR@B) and membership of the Centre of Therapeutic Innovation at University of Bath. DGC also thanks Fundación General CSIC (COMFUTURO Program) for funding."

In the original article, there was a minor error in the caption for **Figure 1**, page 5, as published. The captions for parts (A) and (B) were incorrect. The correct caption is given below.

In the original article, there was a minor error in the caption for **Figure 12**, page 23, as published. The captions for parts (B) and (C) were incorrect. The correct caption is given below.

In the original article, there was an error regarding the affiliation for author "Sofia I. Pascu." As well as affiliation 1, the author is also affiliated with the following institution:

"Centre of Therapeutic Innovations, University of Bath, Bath, United Kingdom."

In the original article, "Cancer Statistics, 2021" was not cited. The citation belongs in the **Introduction**, page 2, paragraph 4, and the corrected sentence reads as follows:

"On average, the 5-years survival rate of patients with localized PCa exceeds 90%. However, patients with distant metastases have significantly lower 5-years survival rates, averaging approximately 31% for prostate cancers (Siegel et al., 2021)."

In the original article, some references were missing. The additional references are listed below.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

1





FIGURE 12 (A) Example of a fluorescent dye (denoted RBITC) used in the synthesis of the fluorescence-activated probe Ab2-RBITC-AuNP, (B) procedure as demonstrated by D. Liu et al. for the synthesis of the AuNP activated probe for early PSA detection (figure adapted from Ref (Liu et al., 2013)) (C) an overview of the procedure in described for the formation of MIP/AuNPs/SPCE (figure adapted from (Nguy et al., 2017)).

REFERENCES

- Liu, D., Huang, X., Wang, Z., Jin, A., Sun, X., Zhu, L., et al. (2013). Gold Nanoparticle-Based Activatable Probe for Sensing Ultralow Levels of Prostate-Specific Antigen. ACS Nano 7, 5568–5576. doi:10.1021/nn401837q
- Nguy, T. P., Van Phi, T., Tram, D. T. N., Eersels, K., Wagner, P., and Lien, T. T. N. (2017). Development of an Impedimetric Sensor for the Label-Free Detection of the Amino Acid Sarcosine With Molecularly Imprinted Polymer Receptors. *Sensors Actuators B Chem.* 246, 461–470. doi:10.1016/j.snb.2017.02.101
- Siegel, R. L., Miller, K. D., Fuchs, H. E., and Jemal, A. (2021). Cancer Statistics, 2021. CA A Cancer J. Clin. 71 (1), 7–33. doi:10.3322/caac.21654
- Theodorescu, D., and Ehdaie, B. (2009). *Prostate Cancer, Clinical Oncology*. Berlin/ Heidelberg, Germany: Springer Berlin Heidelberg.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Calatayud, Neophytou, Nicodemou, Giuffrida, Ge and Pascu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.